Recombinant human parathyroid hormone

From WikiProjectMed
Jump to navigation Jump to search

Recombinant human parathyroid hormone
Clinical data
Trade namesPreotact, Natpara, Natpar
AHFS/Drugs.comMonograph
MedlinePlusa617013
License data
Routes of
administration		Subcutaneous
Drug classHormonal agent
ATC code
Legal status
Legal status
Identifiers
CAS Number
DrugBank
UNII
KEGG
Chemical and physical data
FormulaC408H674N126O126S2
Molar mass9424.76 g·mol−1

Recombinant human parathyroid hormone, sold under the brand name Preotact among others, is an artificially manufactured form of the parathyroid hormone used to treat hypoparathyroidism (under-active parathyroid glands).[1][2][4][5] Recombinant human parathyroid hormone is used in the treatment of osteoporosis in postmenopausal women at high risk of osteoporotic fractures.[3] A significant reduction in the incidence of vertebral fractures has been demonstrated.[3] It is used in combination with calcium and vitamin D supplements.[1][4]

The most common side effects include sensations of tingling, tickling, pricking, or burning of the skin (paraesthesia); low blood calcium; headache; high blood calcium; and nausea.[2]

Recombinant human parathyroid hormone (Preotact) was approved for medical use in the European Union in April 2006.[3] Recombinant human parathyroid hormone (Natpara) was approved for medical use in the United States in January 2015, and in the European Union (as Natpar) in February 2017.[4][6]

Medical uses

Recombinant human parathyroid hormone (Natpara) is indicated as an adjunct to calcium and vitamin D to control hypocalcemia in people with hypoparathyroidism.[1][2] Recombinant human parathyroid hormone (Natpar) is indicated as adjunctive treatment of adults with chronic hypoparathyroidism who cannot be adequately controlled with standard therapy alone.[4]

Recombinant human parathyroid hormone (Preotact) is indicated for the treatment of osteoporosis in postmenopausal women at high risk of fractures,[7] but the marketing authorization has been withdrawn at the manufacturer's request.[3]

Contraindications

Parathyroid hormone treatment should not be initiated in patients:

Adverse effects

The most common side effects include too high or too low blood calcium levels, which can lead to headache, diarrhea, vomiting, paraesthesia (unusual sensations like pins and needles), hypoaesthesia (reduced sense of touch), and high calcium levels in the urine.[4]

In the US, the FDA label for parathyroid hormone contains a black box warning for osteosarcoma (a malignant bone tumor).[1]

Interactions

Parathyroid hormone is a natural peptide that is not metabolised in the liver. It is not protein bound and has a low volume of distribution, therefore no specific drug-drug interactions are suspected. From the knowledge of the mechanism of action, combined use of Preotact and cardiac glycosides may predispose patients to digitalis toxicity if hypercalcemia develops.

Undesirable effects

Hypercalcemia and/or hypercalciuria reflect the known pharmacodynamic actions of parathyroid hormone in the gastrointestinal tract, the kidney and the skeleton, and is therefore an expected undesirable effect. Nausea is another commonly reported adverse reaction to the use of parathyroid hormone.

Pharmacodynamic properties

Mechanism of action

Preotact contains recombinant human parathyroid hormone which is identical to the full-length native 84-amino acid polypeptide. Physiological actions of parathyroid hormone include stimulation of bone formation by direct effects on bone forming cells (osteoblasts) indirectly increasing the intestinal absorption of calcium and increasing the tubular reabsorption of calcium and excretion of phosphate by the kidney.

Full-length human parathyroid hormone

Pharmacodynamic effects

The skeletal effects of parathyroid hormone depend upon the pattern of systemic exposure. Transient elevations in parathyroid hormone levels after subcutaneous injection of Preotact stimulates new bone formation on trabecular and cortical bone surfaces by preferential stimulation of osteoblastic activity over osteoclastic activity.

Effects on serum calcium concentrations

Parathyroid hormone is the principal regulator of serum calcium hemostasis. In response to subcutaneous doses of Preotact (100 micrograms), serum total calcium levels increase gradually and reach peak concentration at approximately 6 to 8 hours after dosing. In general, serum calcium levels return to normal within 24 hours.

Clinical efficacy

In an 18-month double-blind, placebo controlled study, the effects of Preotact on the fracture incidence in 2532 women with postmenopausal osteoporosis was studied. Approximately 19% of patients had a prevalent vertebral fracture at baseline and the mean lumbar T-score of -3.0 in both active and placebo arm. Compared to the placebo group, there was a 61% relative risk reduction of a new vertebral fracture at month 18 for the women in the Preotact group. To prevent one or more new vertebral fractures, 48 women had to be treated for a median of 18 months for the total population. For patients who were already fractured, the number needed to treat was 21.

Effect on bone mineral density

In the same study mentioned above, Preotact increased bone mineral density in the lumbar spine after 18 months treatment by 6.5% compared with a reduction by 0.3% in the placebo group. The difference was statistically significant. The increase of bone mineral density in the hip was also statistically significant compared to placebo, but only around 1.0% at study endpoint. Continued treatment up to 24 months lead to a continued increase in bone mineral density.

Pharmacokinetics

Absorption

Subcutaneous administration of parathyroid hormone into the abdomen produces a rapid increase in plasma parathyroid hormone levels which reach peak at 1 to 2 hours after dosing. The mean half-life is approximately 1.5 hours. The absolute bioavailability of 100 micrograms of Preotact after subcutaneous administration in the abdomen is 55%.

Distribution

The volume of distribution at steady-state following intravenous administration is approximately 5.4 liters. Intersubject variability is about 40%.

Biotransformation

Parathyroid hormone is efficiently removed from the blood by a receptor-mediated process in the liver and is broken down into smaller peptide fragments. The fragments derived from the amino-terminus are further degraded within the cell while the fragments derived from the carboxy-terminus are released back into the blood and cleared by the kidney. These carboxy-terminal fragments are thought to play a role in the regulation of parathyroid hormone activity. Under normal physiological conditions full-length parathyroid hormone H constitutes only 5-30% of the circulating forms of the molecule, while 70-95% is present as carboxy-terminal fragments. Following administration of Preotact, carboxy-terminal fragments make up about 60-90% of the circulating forms of the molecule. Intersubject variability in systemic clearance is about 15%.

Elimination

Parathyroid hormone is metabolised in the liver and to a lesser extent in the kidney. It is not excreted from the body in its intact form. Circulating carboxy-terminal fragments are filtered by the kidney, but are subsequently broken down into even smaller fragments during tubular reuptake. No studies have so far been performed in patients with severe hepatic impairment. The pharmacokinetics of parathyroid hormone in patients with severe chronic kidney disease (creatinine clearance of less than 30 ml/min) has not been investigated either.

Pharmaceutical particulars

Preotact drug cartridge
Preotact drug cartridge

Preotact is delivered in a two chamber, glass ampoule. One chamber contains the active substance in the form of a white powder (with excipients: mannitol, citric acid monohydrate, NaCl, NaOH, HCl). And the other contains the solvent; water for injection. The powder is mixed with the solvent when the ampoule is inserted into the injection device.

See also

References

  1. ^ a b c d e "Natpara (parathyroid hormone)- parathyroid hormone injection, powder, lyophilized, for solution". DailyMed. Retrieved 8 May 2021.
  2. ^ a b c d "FDA approves Natpara to control low blood calcium levels in patients with hypoparathyroidism". U.S. Food and Drug Administration (FDA) (Press release). Archived from the original on 30 January 2015. Retrieved 30 January 2015. Public Domain This article incorporates text from this source, which is in the public domain.
  3. ^ a b c d e "Preotact EPAR". European Medicines Agency. 17 September 2018. Retrieved 3 July 2020.
  4. ^ a b c d e f "Natpar EPAR". European Medicines Agency. 18 December 2013. Retrieved 28 December 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  5. ^ Kim ES, Keating GM (July 2015). "Recombinant Human Parathyroid Hormone (1-84): A Review in Hypoparathyroidism". Drugs. 75 (11): 1293–303. doi:10.1007/s40265-015-0438-2. PMID 26177893. S2CID 2074875.
  6. ^ "First hormone replacement therapy for parathyroid disorder". European Medicines Agency (EMA) (Press release). 24 February 2017. Retrieved 29 December 2023.
  7. ^ "Preotact: European Public Assessment Report". European Medicines Agency. 24 April 2006. Archived from the original on 22 June 2009. Retrieved 12 July 2009.
Retrieved from "https://mdwiki.org/wiki/Recombinant_human_parathyroid_hormone"